Our focus is on the advancement of safer and more cost-effective CAR-T products capable of targeting a wider range of cancers and ultimately enhancing survival rates. We utilize an integrated approach that guides the progression of our products from preclinical evaluation to clinical application. Our primary goal is to pioneer and bring to market innovative cell-based products aimed at treating illness, enhancing patient well-being, and elevating Quality of Life. TC BioPharm is a privately-owned company in the clinical phase of developing cutting-edge allogeneic CAR-T cell therapy products for cancer treatment, along with advancing gamma delta T cell therapies for infectious disease treatment.
TC Biopharm
Headquarters
United Kingdom